ORAMED PHARMACEUTICALS INC.
Congressional Trades
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
Brad KnottHouse · R · NC |
ORMPORAMED PHARMACEUTICALS INC. · Stock |
Sale $15,001 - $50,000 |
Feb 25, 2025 | Jan 10, 2025 | Filing ↗ |
Andrew R. GarbarinoHouse · R · NY |
ORMPORAMED PHARMACEUTICALS INC. · Stock |
Sale $1,001 - $15,000 |
Jan 14, 2022 | Jan 14, 2022 | Filing ↗ |
Andrew R. GarbarinoHouse · R · NY |
ORMPORAMED PHARMACEUTICALS INC. · Stock |
Sale $1,001 - $15,000 |
Nov 3, 2021 | Oct 1, 2021 | Filing ↗ |
Andrew R. GarbarinoHouse · R · NY |
ORMPORAMED PHARMACEUTICALS INC. · Stock |
Purchase $1,001 - $15,000 |
May 24, 2021 | Apr 23, 2021 | Filing ↗ |
Whale Activity
- Increased33
- New18
- Held23
- Decreased17
- Closed10
- No prior filing2
| Filer | Shares | Value | Change |
|---|---|---|---|
| MERCER GLOBAL ADVISORS INC /ADV | 3.8M | $17.8M | increased |
| Aquamarine Financial (Cayman) Ltd | 2.7M | $12.4M | increased |
| Murchinson Ltd. | 2.1M | $10.0M | increased |
| Gem Investment Advisors, LLC | 2.0M | $9.3M | held |
| BlackRock, Inc. | 1.8M | $8.6M | increased |
| BML Capital Management, LLC | 884.4K | $4.1M | increased |
| BOOTHBAY FUND MANAGEMENT, LLC | 820.6K | $3.8M | increased |
| GEODE CAPITAL MANAGEMENT, LLC | 500.9K | $2.3M | increased |
| STATE STREET CORP | 466.7K | $2.2M | increased |
| RENAISSANCE TECHNOLOGIES LLC | 294.3K | $1.4M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 239.1K | $1.1M | increased |
| Rathbones Group PLC | 233.0K | $1.1M | held |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Gabay AvrahamChief Financial Officer | Sale | −20.0K | $4.51 | $90K | Oct 1, 2026 | Form 4 ↗ |
| Hexter JoshuaCOO & CBO | Sale | −30.0K | $4.51 | $135K | Oct 1, 2026 | Form 4 ↗ |
| KIDRON NADAVPresident and CEO · Director | Grant / award | +368.8K | — | — | Sep 24, 2026 | Form 4 ↗ |
| KIDRON NADAVPresident and CEO · Director | Grant / award | +349.5K | — | — | Sep 24, 2026 | Form 4 ↗ |
| Hexter JoshuaCOO & CBO | Grant / award | +209.3K | — | — | Sep 24, 2026 | Form 4 ↗ |
| Hexter JoshuaCOO & CBO | Grant / award | +75.5K | — | — | Sep 24, 2026 | Form 4 ↗ |
| Kidron MiriamChief Scientific Officer · Director | Grant / award | +209.3K | — | — | Sep 24, 2026 | Form 4 ↗ |
| Kidron MiriamChief Scientific Officer · Director | Grant / award | +208.1K | — | — | Sep 24, 2026 | Form 4 ↗ |
| Gabay AvrahamChief Financial Officer | Grant / award | +209.3K | — | — | Sep 24, 2026 | Form 4 ↗ |
| Hexter JoshuaCOO & CBO | Option exercise | +50.0K | $3.69 | $185K | Jul 2, 2026 | Form 4 ↗ |
| Hexter JoshuaCOO & CBO | Sale | −137.0K | $4.46 | $611K | Jul 1, 2026 | Form 4 ↗ |
| Gabay AvrahamChief Financial Officer | Sale | −73.4K | $4.51 | $331K | Jul 1, 2026 | Form 4 ↗ |
| KIDRON NADAVPresident and CEO · Director | Tax withholding | −44.8K | $3.31 | $148K | Mar 30, 2026 | Form 4 ↗ |
| Kidron MiriamChief Scientific Officer · Director | Tax withholding | −435.1K | $3.31 | $1.4M | Mar 30, 2026 | Form 4 ↗ |
| Kidron MiriamChief Scientific Officer · Director | Grant / award | +119.6K | $0.00 | $0 | Mar 17, 2026 | Form 4 ↗ |
| KIDRON NADAVPresident and CEO · Director | Grant / award | +167.0K | $0.00 | $0 | Mar 17, 2026 | Form 4 ↗ |
| Hexter JoshuaCOO & CBO | Grant / award | +95.9K | $0.00 | $0 | Mar 17, 2026 | Form 4 ↗ |
| Gabay AvrahamChief Financial Officer | Grant / award | +95.9K | $0.00 | $0 | Mar 17, 2026 | Form 4 ↗ |
| KIDRON NADAVPresident and CEO · Director | Gift | −100.0K | $0.00 | $0 | Mar 12, 2026 | Form 4 ↗ |
| KIDRON NADAVPresident and CEO · Director | Option exercise | +109.0K | $0.00 | $0 | Jan 22, 2026 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| iShares Russell 2000 ETF iShares Trust | 634.6K | $3.1M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 378.5K | $1.5M | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF iShares Trust | 318.6K | $1.5M | 0.01% | Jun 30, 2026 |
| VANGUARD RUSSELL 2000 INDEX FUND VANGUARD SCOTTSDALE FUNDS | 194.0K | $974K | 0.01% | Aug 31, 2026 |
| iShares Micro-Cap ETF iShares Trust | 115.0K | $553K | 0.04% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund SCHWAB CAPITAL TRUST | 83.6K | $340K | 0.00% | Jul 31, 2026 |
| Master Small Cap Index Series Quantitative Master Series LLC | 63.6K | $306K | 0.01% | Jun 30, 2026 |
| Goldman Sachs ActiveBeta(R) U.S. Small Cap Equity ETF Goldman Sachs ETF Trust | 58.0K | $291K | 0.03% | Aug 31, 2026 |
| Avantis U.S. Small Cap Equity ETF American Century ETF Trust | 55.6K | $279K | 0.01% | Aug 31, 2026 |
| Fidelity Small Cap Value Index Fund Fidelity Salem Street Trust | 48.7K | $234K | 0.01% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list ORMP's shares (CUSIP 68403P203), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
- Aquamarine Financial (Cayman) LtdSCHEDULE 13G/A · passive (13G) · 2.7M shares6.4%
Nov 13, 2026 · ↗ - Aquamarine Financial (Cayman) LtdSCHEDULE 13G/A · passive (13G) · 2.5M shares6.0%
Aug 14, 2026 · ↗ - Leonard Braden MichaelSCHEDULE 13G/A · passive (13G) · 1.0M shares2.5%
Jun 29, 2026 · ↗ - BML Investment Partners, L.P.SCHEDULE 13G/A · passive (13G) · 866.3K shares2.1%
Jun 29, 2026 · ↗ - Aquamarine Financial (Cayman) LtdSCHEDULE 13G · passive (13G) · 2.0M shares5.1%
May 15, 2026 · ↗
Corporate Lobbying
No lobbying filings found naming ORAMED PHARMACEUTICALS INC. as the client.
Government Contracts
No federal contract awards found for ORAMED PHARMACEUTICALS INC..
U.S. Patents
No USPTO patent applications found for ORAMED PHARMACEUTICALS INC..
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.0M | n/a | $1.3M | $2.7M | $2.7M |
| Operating income | -$15.1M | -$12.8M | -$15.8M | -$40.6M | -$24.2M |
| Net income | $64.0M | -$19.1M | $5.1M | -$36.6M | -$23.0M |
| Diluted EPS | $1.50 | -$0.48 | $0.14 | -$0.94 | n/a |
| Operating cash flow | -$9.1M | -$8.4M | -$10.3M | -$27.9M | -$21.2M |
| Cash and equivalents | $45.9M | $54.4M | $9.1M | $40.5M | $77.2M |
| Total assets | $230.9M | $155.3M | $220.6M | $161.6M | $128.0M |
| Shareholders' equity | $199.7M | $146.3M | $163.8M | $151.8M | $115.8M |
As ORAMED PHARMACEUTICALS INC. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Mar 26, 2026 ↗
Stock Splits
- 1-for-12Reverse splitJan 23, 2013
Split dates and ratios from the price history · Close Prices from Tiingo.com


